These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35989659)

  • 41. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of Heterozygosity of
    Mizrahi AG; Hamad H; Gugenheim A; Nisman B; Kuznetz A; David IB; Gelfend Y; Cohen S; Zick A; Sheva K; Nechushtan H; Peretz T; Meirovitz A
    Anticancer Res; 2022 Nov; 42(11):5257-5263. PubMed ID: 36288893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular mechanism of PARP inhibitor resistance.
    Huang Y; Chen S; Yao N; Lin S; Zhang J; Xu C; Wu C; Chen G; Zhou D
    Oncoscience; 2024; 11():69-91. PubMed ID: 39318358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in the use of PARP inhibitor therapy for breast cancer.
    McCann KE; Hurvitz SA
    Drugs Context; 2018; 7():212540. PubMed ID: 30116283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
    Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
    Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
    Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
    J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 50. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
    AlGhamdi A; AlMubayedh H
    Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
    Rescigno P; Chandler R; de Bono J
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):339-343. PubMed ID: 29979319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of PARP inhibitors in advanced prostate cancer.
    Bourlon MT; Valdez P; Castro E
    Ther Adv Med Oncol; 2024; 16():17588359231221337. PubMed ID: 38205078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
    Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    Ziadeh T; Kourie HR
    Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PARP Inhibitors in Ovarian Cancer.
    Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
    Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    Liu P; Lin C; Liu L; Lu Z; Tu Z; Liu H
    J Biol Chem; 2022 Sep; 298(9):102354. PubMed ID: 35952757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.